China approves new targeted anticancer drug for lymphoma patients
Guangzhou (ANTARA) - Rocbrutinib, a new targeted anti-cancer drug for lymphoma patients, received marketing approval on Thursday from China’s National Medical Products Administration (NMPA).
This revolutionary drug offers new treatment opportunities for lymphoma patients who have developed resistance to other medications.
Developed by the clinical-stage pharmaceutical company Lupeng Pharmaceutical, based in Guangzhou, Guangdong Province, southern China, the oral medication is capable of inhibiting cancer cell survival mechanisms. It works by binding to cancer cells and preventing a target protein known as BTK within the cells through two different pathways.
Specifically, on one hand, the drug can bind strongly and irreversibly to the target. Even when the target has undergone several mutations related to resistance, the drug remains capable of binding to and inhibiting the target, ensuring continued effectiveness for resistant patients.
The approval is expected to provide new options for lymphoma patients experiencing resistance to previous treatments and who have few effective treatment alternatives remaining.
The drug has been included in the NMPA’s Breakthrough Therapy Designations (BTD). Results from Phase II clinical trials showed an objective response rate of 63.9 per cent, a complete response rate of 23 per cent, and a median duration of response of 16.5 months.
In other words, for every 100 lymphoma patients who are resistant to other drugs and have few treatment options, approximately 64 experience significant tumour shrinkage, 23 experience total tumour disappearance based on imaging, and about half experience clinical benefits lasting more than 16.5 months.
In 2025, a total of 76 innovative drugs have been authorised in China, setting a new record for the country’s pharmaceutical industry.
Source: jawawa.id (https://jawawa.id/newsitem/china-approves-new-targeted-anticancer-drug-for-lymphoma-patients-1780681866)
Originally published by Antara (Indonesian) (https://www.antaranews.com/berita/5596459/china-beri-izin-edar-obat-antikanker-bagi-pasien-limfoma), translated from Indonesian